Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952731 · ClinicalTrials.gov registry record · Phase 2
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00952731 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 27 participants.
The verdict
NCT00952731, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works compared with tamoxifen citrate in treating women with newly diagnosed ductal breast carcinoma in situ. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. It is not yet known whether topical tamoxifen causes less damage to normal tissue than systemic tamoxifen in treating patients with ductal carcinoma in situ.
Interventions
- DRUG tamoxifen citrate
- DRUG placebo gel
- DRUG oral placebo
- DRUG afimoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952731
The ClinicalTrials.gov registry entry for NCT00952731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which tamoxifen citrate is the first listed.
NCT00952731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00952731 about?
NCT00952731 is a clinical study titled "4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ". This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works compared with tamoxifen citrate in treating women with newly diagnosed ductal breast carcinoma in situ. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer...
What is the current status of trial NCT00952731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-12.
What interventions are being tested in trial NCT00952731?
The interventions under investigation include: tamoxifen citrate (DRUG), placebo gel (DRUG), oral placebo (DRUG), afimoxifene (DRUG).
Who is sponsoring clinical trial NCT00952731?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.